Will Health Insurers Inhibit Medical Progress?

Very few patients have noticed an epic struggle taking place among policy wonks, lobbyists, hedge fund managers and economists in the drug and insurance industries.  Some want to describe the fight as being about drug pricing and value, but it might actually be about limiting access to newly approved and emerging myeloma therapies.

Patients are mostly in the dark because they have been intentionally left out of the argument.  But they can find it if they know where to look.

The controversy revolves around recommendations by the Institute for Clinical and Economic Review (ICER), a Boston-based nonprofit that is mostly supported by the insurance industry and investor-funded foundations, to create “value-based” or “indication-specific pricing” drug reimbursement rules for insurers.

Read More at Myeloma Crowd

About the Author:
Greg Brozeit is an independent consultant who specializes in strategic outreach, community building, and public policy advocacy. He has broad experience working with myeloma patients, physicians, and researchers. Most recently he advised Dr. Bart Barlogie at the Myeloma Institute for Research and Therapy. He worked for more than 14 years with the International Myeloma Foundation. Greg founded its advocacy program and later serving as the inaugural director of IMF Europe. Greg has also worked for a national civic education organization, in aging research advocacy, as a U.S. Senate legislative staff member, and as a secondary school teacher. He is married with two sons and lives in Northeast Ohio.
Close Menu